TheraRadar
← Back
Data updated: Sep 20, 2026

BOSTAL DRUG

Generics

BOSTAL DRUG is a generic drug manufacturer focused on Metabolic.

2026
Since
1
Drugs
-
Trials
0
New Drugs (2yr)

BOSTAL DRUG's Key Drugs

BOSTAL DRUG's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

BOSTAL DRUG's Recent FDA Approvals

New NDA/BLA approvals for BOSTAL DRUG over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

BOSTAL DRUG's Therapeutic Areas

BOSTAL DRUG's approved drugs and pipeline span 1 therapeutic area, led by Metabolic. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Metabolic 100%
0 drugs Phase 1: 1

BOSTAL DRUG's Top Competitors

BOSTAL DRUG's closest competitors by therapeutic-area and drug-target overlap include Merck, Baxter, and Johnson & Johnson. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

BOSTAL DRUG Pipeline Snapshot

BOSTAL DRUG has 1 active clinical program from ClinicalTrials.gov — 0 Phase 3, 0 Phase 2 and 1 Phase 1.

0
Phase 3
0
Phase 2
1
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Metabolic pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling